vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and HARVARD BIOSCIENCE INC (HBIO). Click either name above to swap in a different company.
Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $23.7M, roughly 2.6× HARVARD BIOSCIENCE INC). HARVARD BIOSCIENCE INC runs the higher net margin — -12.0% vs -70.9%, a 58.9% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs -3.3%). HARVARD BIOSCIENCE INC produced more free cash flow last quarter ($-545.0K vs $-1.8M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs -1.6%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.
CTKB vs HBIO — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $23.7M |
| Net Profit | $-44.1M | $-2.8M |
| Gross Margin | 52.9% | 59.7% |
| Operating Margin | -9.0% | 7.2% |
| Net Margin | -70.9% | -12.0% |
| Revenue YoY | 8.1% | -3.3% |
| Net Profit YoY | -557.1% | -15916.7% |
| EPS (diluted) | — | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $23.7M | ||
| Q3 25 | $52.3M | $20.6M | ||
| Q2 25 | $45.6M | $20.4M | ||
| Q1 25 | $41.5M | $21.8M | ||
| Q4 24 | $57.5M | $24.6M | ||
| Q3 24 | $51.5M | $22.0M | ||
| Q2 24 | $46.6M | $23.1M | ||
| Q1 24 | $44.9M | $24.5M |
| Q4 25 | $-44.1M | $-2.8M | ||
| Q3 25 | $-5.5M | $-1.2M | ||
| Q2 25 | $-5.6M | $-2.3M | ||
| Q1 25 | $-11.4M | $-50.3M | ||
| Q4 24 | $9.6M | $18.0K | ||
| Q3 24 | $941.0K | $-4.8M | ||
| Q2 24 | $-10.4M | $-2.9M | ||
| Q1 24 | $-6.2M | $-4.7M |
| Q4 25 | 52.9% | 59.7% | ||
| Q3 25 | 52.7% | 58.4% | ||
| Q2 25 | 52.3% | 56.4% | ||
| Q1 25 | 48.6% | 56.0% | ||
| Q4 24 | 58.5% | 57.1% | ||
| Q3 24 | 56.3% | 58.1% | ||
| Q2 24 | 54.6% | 57.2% | ||
| Q1 24 | 51.3% | 60.3% |
| Q4 25 | -9.0% | 7.2% | ||
| Q3 25 | -17.6% | 1.0% | ||
| Q2 25 | -23.3% | -4.0% | ||
| Q1 25 | -36.1% | -228.1% | ||
| Q4 24 | 5.2% | 0.0% | ||
| Q3 24 | -8.2% | -8.5% | ||
| Q2 24 | -18.3% | -9.0% | ||
| Q1 24 | -23.9% | -9.3% |
| Q4 25 | -70.9% | -12.0% | ||
| Q3 25 | -10.5% | -6.0% | ||
| Q2 25 | -12.2% | -11.2% | ||
| Q1 25 | -27.5% | -231.2% | ||
| Q4 24 | 16.8% | 0.1% | ||
| Q3 24 | 1.8% | -21.9% | ||
| Q2 24 | -22.4% | -12.7% | ||
| Q1 24 | -13.8% | -19.1% |
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $-0.05 | ||
| Q1 25 | — | $-1.14 | ||
| Q4 24 | — | $0.01 | ||
| Q3 24 | — | $-0.11 | ||
| Q2 24 | — | $-0.07 | ||
| Q1 24 | — | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $8.6M |
| Total DebtLower is stronger | — | $35.9M |
| Stockholders' EquityBook value | $341.7M | $13.7M |
| Total Assets | $461.5M | $80.1M |
| Debt / EquityLower = less leverage | — | 2.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | $8.6M | ||
| Q3 25 | $93.3M | $6.8M | ||
| Q2 25 | $75.5M | $7.4M | ||
| Q1 25 | $95.3M | $5.5M | ||
| Q4 24 | $98.7M | $4.1M | ||
| Q3 24 | $162.3M | $4.6M | ||
| Q2 24 | $177.9M | $4.0M | ||
| Q1 24 | $168.8M | $4.3M |
| Q4 25 | — | $35.9M | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $34.9M | ||
| Q1 25 | — | $36.4M | ||
| Q4 24 | — | $37.0M | ||
| Q3 24 | — | $34.9M | ||
| Q2 24 | — | $35.7M | ||
| Q1 24 | — | $35.6M |
| Q4 25 | $341.7M | $13.7M | ||
| Q3 25 | $378.6M | $14.1M | ||
| Q2 25 | $377.6M | $15.7M | ||
| Q1 25 | $379.6M | $14.8M | ||
| Q4 24 | $395.7M | $63.3M | ||
| Q3 24 | $385.5M | $65.3M | ||
| Q2 24 | $389.1M | $67.2M | ||
| Q1 24 | $392.6M | $68.8M |
| Q4 25 | $461.5M | $80.1M | ||
| Q3 25 | $494.9M | $78.0M | ||
| Q2 25 | $493.3M | $80.1M | ||
| Q1 25 | $482.6M | $79.8M | ||
| Q4 24 | $499.5M | $126.6M | ||
| Q3 24 | $491.2M | $131.2M | ||
| Q2 24 | $483.7M | $128.9M | ||
| Q1 24 | $492.1M | $133.2M |
| Q4 25 | — | 2.61× | ||
| Q3 25 | — | 2.41× | ||
| Q2 25 | — | 2.22× | ||
| Q1 25 | — | 2.45× | ||
| Q4 24 | — | 0.58× | ||
| Q3 24 | — | 0.53× | ||
| Q2 24 | — | 0.53× | ||
| Q1 24 | — | 0.52× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $-96.0K |
| Free Cash FlowOCF − Capex | $-1.8M | $-545.0K |
| FCF MarginFCF / Revenue | -2.9% | -2.3% |
| Capex IntensityCapex / Revenue | 1.6% | 1.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | $5.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $-96.0K | ||
| Q3 25 | $-3.9M | $1.1M | ||
| Q2 25 | $108.0K | $2.8M | ||
| Q1 25 | $-125.0K | $3.0M | ||
| Q4 24 | $2.0M | $1.7M | ||
| Q3 24 | $13.2M | $-842.0K | ||
| Q2 24 | $6.2M | $-846.0K | ||
| Q1 24 | $4.0M | $1.4M |
| Q4 25 | $-1.8M | $-545.0K | ||
| Q3 25 | $-4.6M | $877.0K | ||
| Q2 25 | $-1.5M | $2.7M | ||
| Q1 25 | $-974.0K | $2.5M | ||
| Q4 24 | $1.1M | $1.4M | ||
| Q3 24 | $12.2M | $-1.7M | ||
| Q2 24 | $5.2M | $-1.7M | ||
| Q1 24 | $3.4M | $758.0K |
| Q4 25 | -2.9% | -2.3% | ||
| Q3 25 | -8.7% | 4.3% | ||
| Q2 25 | -3.2% | 13.0% | ||
| Q1 25 | -2.3% | 11.4% | ||
| Q4 24 | 1.9% | 5.8% | ||
| Q3 24 | 23.7% | -7.8% | ||
| Q2 24 | 11.0% | -7.2% | ||
| Q1 24 | 7.6% | 3.1% |
| Q4 25 | 1.6% | 1.9% | ||
| Q3 25 | 1.3% | 1.0% | ||
| Q2 25 | 3.5% | 0.4% | ||
| Q1 25 | 2.0% | 2.4% | ||
| Q4 24 | 1.6% | 1.2% | ||
| Q3 24 | 2.0% | 4.0% | ||
| Q2 24 | 2.3% | 3.5% | ||
| Q1 24 | 1.3% | 2.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | 95.83× | ||
| Q3 24 | 14.05× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
HBIO
| Instruments Equipment Software And Accessories | $21.6M | 91% |
| Service Maintenance And Warranty Contracts | $2.1M | 9% |
